Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra warning letters

This article was originally published in The Tan Sheet

Executive Summary

Universal Nutrition, which received FDA warning letter to discontinue ephedra athletic performance claims, says it has submitted response to agency pledging compliance and requesting clarification on some points; firm also has revised language on its Web site, labeling. New Brunswick, N.J.-based firm said it is debating whether or not to exit ephedra market. Other FDA letter recipients including American Body Building, Advanced Pharmaceuticals have issued similar responses to agency, which sent the letters in late February (1"The Tan Sheet" March 3, 2003, p. 8)...
Advertisement

Related Content

Ephedra Athletic Performance Claims Targeted In FDA Warning Letters
Ephedra Athletic Performance Claims Targeted In FDA Warning Letters

Topics

Advertisement
UsernamePublicRestriction

Register

PS095279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel